Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11298475 | 0.76 | TSHR (0.31) | ALDH1A1TDP1 | |
| SCHEMBL7684525 | 0.71 | — | — | |
| SCHEMBL10656553 | 0.64 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL13282786 | 0.62 | — | — | |
| SCHEMBL8369703 | 0.61 | — | — | |
| SCHEMBL9743198 | 0.61 | — | — | |
| SCHEMBL11802296 | 0.60 | LMNA (0.33) | ALDH1A1TDP1 | |
| SCHEMBL2569378 | 0.60 | — | — | |
| SCHEMBL7701653 | 0.60 | GSK3A (0.32) | — | |
| SCHEMBL11102852 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020007071-A1 | Benzimidzolyl neuropeptide Y receptor antagonists | BRITTON THOMAS CHARLES (US) | 2002-01-17 | — | — | US | disclosed |
| US-6255494-B1 | SUBSTITUTED BENZIMIDAZOLES USEFUL IN TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH EXCESS OF NEUROPEPTIDE Y (AROUND ARTERIES IN HEART, RESPIRATORY TRACT, GASTROINTESTINAL TRACT AND GENITOURINARY TRACT); ETIOLOGY OF PSYCHIATRIC DISORDERS | ELI LILLY AND COMPANY | 2001-07-03 | — | — | US | disclosed |
| US-6030992-A | ANTAGONISTS FOR THE BINDING OF NEUROKININ-2 RECEPTOR; SLEEP DISORDERS; BENZIMIDES, 2- OR 3-ALKOXYBENZIMIDES AND 2,3-DIALKOXYBENZIMIDES | ELI LILLY AND COMPANY (US) | 2000-02-29 | — | — | US | disclosed |
| US-6025379-A | A SUBSTITUTED BENZIMIDAZOLE, TACHYKININ RECEPTOR ANTAGONISTS, | ELI LILLY AND COMPANY (US) | 2000-02-15 | — | — | US | disclosed |
| EP-0871442-A1 | BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997033873-A1 | METHODS OF TREATING OR PREVENTING INTERSTITIAL CYSTITIS | ELI LILLY AND COMPANY (US) | 1997-09-18 | — | — | WO | disclosed |
| WO-1997025041-A1 | BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
| US-5552426-A | NERVOUS SYSTEM DISORDERS USING IMIDAZOLE DERIVITIVES | ELI LILLY AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0694535-A1 | Non-peptidyl tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-01-31 | — | — | EP | disclosed |
| US-4492708-A | Antiviral benzimidazoles | ELI LILLY AND COMPANY (US) | 1985-01-08 | — | — | US | disclosed |
| US-4401817-A | ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1983-08-30 | — | — | US | disclosed |
| US-4338315-A | RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-4338329-A | COMBATTING RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-4293558-A | Antiviral thiazolinyl benzimidazoles and derivatives | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| US-4289782-A | PARTICULARLY FOR INHIBITING GROWTH OF RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| US-4230868-A | α-Alkyl-α-hydroxybenzyl-substituted 1-sulfonylbenzimidazoles | ELI LILLY AND COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| US-4216313-A | Antiviral thiazinyl benzimidazoles | ELI LILLY AND COMPANY (US) | 1980-08-05 | — | — | US | disclosed |
| US-4174454-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1979-11-13 | — | — | US | disclosed |
| US-4150028-A | Antiviral thiazolinyl benzimidazoles | ELI LILLY AND COMPANY (US) | 1979-04-17 | — | — | US | disclosed |
| US-4118742-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007071-A1 | Benzimidzolyl neuropeptide Y receptor antagonists | NPY1R, NPY2R, NPY5R | ALDH1A1 4251/4885TDP1 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.